These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 34741996)

  • 1. Therapeutic applications of biosimilar monoclonal antibodies: Systematic review of the efficacy, safety, and immunogenicity in autoimmune disorders.
    Mirjalili SZ; Sabourian R; Sadeghalvad M; Rezaei N
    Int Immunopharmacol; 2021 Dec; 101(Pt B):108305. PubMed ID: 34741996
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety, Immunogenicity and Interchangeability of Biosimilar Monoclonal Antibodies and Fusion Proteins: A Regulatory Perspective.
    Kurki P; Barry S; Bourges I; Tsantili P; Wolff-Holz E
    Drugs; 2021 Nov; 81(16):1881-1896. PubMed ID: 34596876
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Biosimilars in rheumatology and other fields of medicine].
    Milchert M; Fliciński J; Brzosko M
    Postepy Hig Med Dosw (Online); 2014 Jul; 68():970-5. PubMed ID: 25055035
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expert perspectives on biosimilar monoclonal antibodies in breast cancer.
    Cortés J; Curigliano G; Diéras V
    Breast Cancer Res Treat; 2014 Apr; 144(2):233-9. PubMed ID: 24562824
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Biosimilars in the European Union: current situation and challenges].
    Wolff-Holz E; Weise M
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2020 Nov; 63(11):1365-1372. PubMed ID: 33034693
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative Efficacy and Safety of Biosimilar Rituximab and Originator Rituximab in Rheumatoid Arthritis and Non-Hodgkin's Lymphoma: A Systematic Review and Meta-analysis.
    Lee S; Lee H; Kim E
    BioDrugs; 2019 Oct; 33(5):469-483. PubMed ID: 31446557
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and efficacy of biosimilars in oncology.
    Schellekens H; Smolen JS; Dicato M; Rifkin RM
    Lancet Oncol; 2016 Nov; 17(11):e502-e509. PubMed ID: 27819248
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biosimilar Monoclonal Antibodies for Inflammatory Bowel Disease: Current Comfort and Future Prospects.
    Gecse KB; Lakatos PL
    Drugs; 2016 Oct; 76(15):1413-1420. PubMed ID: 27638739
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapeutic monoclonal antibodies: strategies and challenges for biosimilars development.
    Calvo B; Zuñiga L
    Curr Med Chem; 2012; 19(26):4445-50. PubMed ID: 22978327
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Data Driven Approach to Support Tailored Clinical Programs for Biosimilar Monoclonal Antibodies.
    Guillen E; Ekman N; Barry S; Weise M; Wolff-Holz E
    Clin Pharmacol Ther; 2023 Jan; 113(1):108-123. PubMed ID: 36546547
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biosimilars in the therapy of inflammatory bowel diseases.
    Hlavaty T; Letkovsky J
    Eur J Gastroenterol Hepatol; 2014 Jun; 26(6):581-7. PubMed ID: 24722561
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Emerging trends and therapeutic applications of monoclonal antibodies.
    Mekala JR; Nalluri HP; Reddy PN; S B S; N S SK; G V S D SK; Dhiman R; Chamarthy S; Komaragiri RR; Manyam RR; Dirisala VR
    Gene; 2024 Oct; 925():148607. PubMed ID: 38797505
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biosimilars of adalimumab: the upcoming challenge in IBD.
    Fiorino G; Gilardi D; Correale C; Furfaro F; Roda G; Loy L; Argollo M; Allocca M; Peyrin-Biroulet L; Danese S
    Expert Opin Biol Ther; 2019 Oct; 19(10):1023-1030. PubMed ID: 30601098
    [No Abstract]   [Full Text] [Related]  

  • 14. Progress with infliximab biosimilars for inflammatory bowel disease.
    Kurti Z; Gonczi L; Lakatos PL
    Expert Opin Biol Ther; 2018 Jun; 18(6):633-640. PubMed ID: 29688797
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy, Safety and Immunogenicity of Biosimilars in Inflammatory Bowel Diseases: A Systematic Review.
    Martelli L; Peyrin-Biroulet L
    Curr Med Chem; 2019; 26(2):270-279. PubMed ID: 27758715
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biosimilar monoclonal antibodies: preclinical and clinical development aspects.
    Gonçalves J; Araújo F; Cutolo M; Fonseca JE
    Clin Exp Rheumatol; 2016; 34(4):698-705. PubMed ID: 27383278
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An overview of patents on therapeutic monoclonal antibodies in Europe: are they a hurdle to biosimilar market entry?
    Moorkens E; Vulto AG; Huys I
    MAbs; 2020; 12(1):1743517. PubMed ID: 32306833
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and Safety of Anti-cancer Biosimilars Compared to Reference Biologics in Oncology: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
    Yang J; Yu S; Yang Z; Yan Y; Chen Y; Zeng H; Ma F; Shi Y; Shi Y; Zhang Z; Sun F
    BioDrugs; 2019 Aug; 33(4):357-371. PubMed ID: 31175632
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Language of Biosimilars: Clarification, Definitions, and Regulatory Aspects.
    Declerck P; Danesi R; Petersel D; Jacobs I
    Drugs; 2017 Apr; 77(6):671-677. PubMed ID: 28258517
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Investigation of Immunogenicity Assessment of Biosimilar Monoclonal Antibodies in the United States.
    Cheng CA; Jiang AL; Liu YR; Chang LC
    Clin Pharmacol Ther; 2023 Dec; 114(6):1274-1284. PubMed ID: 37634125
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.